Erdheim-Chester Disease clinical trials at UCSF

1 research study open to eligible people

Erdheim-Chester disease is a rare condition in which immune cells collect and cause tissue damage. UCSF is testing drugs that act on the abnormal cells, including a medicine called cobimetinib for related disorders. UCSF is monitoring scans, lab values, and symptoms in adults and children who take part.

Showing trials for

  • Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders

    open to all eligible people

    This is a research study of a drug called cobimetinib in children and adults diagnosed with Langerhans cell histiocytosis (LCH), and other histiocytic disorders that has returned or does not respond to treatment. Cobimetinib blocks activation of a protein called Mitogen-activated protein kinase (MEK) that is part of incorrect growth signals in histiocytosis cells. Four different groups of patients will be enrolled.

    San Francisco, California and other locations

Our lead scientists for Erdheim-Chester Disease research studies include .

Last updated: